Meng Chen, MD
Allergy/Immunology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chen’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A133233 · Current
Licensed to practise in California · since 2014 · expires 2028-09-30 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$10,010
Medicare paid this office $10,010 for 54 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 30 | $5,195 | $115 |
| Short return visit (20+ min) | 12 | $924 | $71 |
Who their Medicare patients are
54 Original Medicare patients in 2024. Average age 68 · Women 65% · Also on Medicaid 30% · Health risk score 2.03. Sicker patients than 9 in 10 peers; the typical allergy/ immunology clinician is at 1.
Conditions among them: High blood pressure 65% · Coronary heart disease 33% · Depression 30% · Diabetes 28% · Heart failure 24% · Chronic kidney disease 24% · COPD 22%.
The office billed $41,182, Medicare allowed $13,294 and paid $10,010; for 88 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 54 | 88 | 68 | 2.03 | $41,182 | $10,010 |
| 2023 | 73 | 347 | 70 | 1.66 | $86,068 | $15,585 |
| 2022 | 72 | 370 | 67 | 1.74 | $99,881 | $19,335 |
| 2021 | 89 | 256 | 69 | 1.46 | $79,765 | $15,308 |
| 2020 | 25 | 82 | 67 | 1.43 | $30,881 | $5,494 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 39 | $5,428 | $109 |
| New patient visit (60+ min) | 18 | $3,314 | $184 |
| Telehealth originating site facility fee | 58 | $1,677 | $21 |
| Short return visit (20+ min) | 11 | $1,135 | $76 |
2022: 5 services
| New patient visit (60+ min) | 27 | $5,356 | $198 |
| Return visit (30+ min) | 29 | $4,481 | $121 |
| New patient visit (45+ min) | 17 | $2,493 | $147 |
| Telehealth originating site facility fee | 55 | $1,809 | $21 |
| Short return visit (20+ min) | 14 | $1,123 | $70 |
2021: 5 services
| Return visit (30+ min) | 22 | $3,677 | $127 |
| New patient visit (45+ min) | 21 | $3,134 | $149 |
| New patient visit (60+ min) | 15 | $2,926 | $195 |
| Telehealth originating site facility fee | 51 | $1,627 | $22 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 27 | $624 | $23 |
2020: 3 services
| New patient visit (45+ min) | 13 | $1,850 | $142 |
| Return visit (30+ min) | 14 | $1,760 | $104 |
| Telehealth originating site facility fee | 24 | $859 | $21 |
Medicaid work
$1,177 in 2024
Medicaid paid $1,177 for 15 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 15 | $1,177 |
| 2024 | 15 | 1 | 15 | $1,177 |
| 2023 | 94 | 2 | 15 | $2,915 |
| 2022 | 54 | 1 | 20 | $1,501 |
| 2021 | 116 | 1 | 21 | $3,275 |
| 2020 | 50 | 1 | 18 | $1,616 |
See the largest Medicaid services in earlier years
2023
| Telehealth originating site facility fee | 82 | $2,199 |
| Return visit (30+ min) | 12 | $716 |
2022
| Telehealth originating site facility fee | 54 | $1,501 |
2021
| Telehealth originating site facility fee | 116 | $3,275 |
2020
| Telehealth originating site facility fee | 50 | $1,616 |
Drugs they prescribed that Part D paid
$168,578
Pharmacies billed $168,578 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 195) in 2024. At or below the middle of the specialty; the typical allergy/ immunology clinician is at 0%.
119 generic and 76 brand-name prescriptions · $168,578 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xolair | 23 | $70,369 | $3,060 |
| Dupixent | 13 | $46,490 | $3,576 |
| Epinephrine | 13 | $2,809 | $216 |
| Azelastine | 35 | $1,457 | $42 |
| Ipratropium | 24 | $558 | $23 |
See all 6 drugs
| Xolair | 23 | $70,369 | $3,060 |
| Dupixent | 13 | $46,490 | $3,576 |
| Epinephrine | 13 | $2,809 | $216 |
| Azelastine | 35 | $1,457 | $42 |
| Ipratropium | 24 | $558 | $23 |
| Fluticasone Propionate | 26 | $243 | $9 |
Year by year
| 2024 | 195 | 39 | 0% (0) | 39% | $168,578 |
| 2023 | 186 | 38 | 0% (0) | 33% | $208,156 |
| 2022 | 127 | 27 | 0% (0) | 47% | $123,329 |
| 2021 | 110 | 29 | 0% (0) | 37% | $72,920 |
| 2020 | 15 | None | 0% (0) | None | $1,017 |
| 2019 | 17 | None | 0% (0) | None | $1,929 |
| 2018 | 64 | 20 | 0% (0) | 30% | $7,879 |
| 2017 | 47 | 20 | None | 43% | $4,617 |
| 2016 | 44 | 23 | None | 36% | $5,733 |
| 2015 | 12 | None | 0% (0) | None | $615 |
| 2014 | 15 | None | 0% (0) | None | $1,633 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Dupixent | 12 | $50,225 | $4,185 |
| Nucala | 11 | $46,494 | $4,227 |
| Azelastine | 39 | $1,560 | $40 |
| Epinephrine | 11 | $1,466 | $133 |
| Fluticasone Propionate | 32 | $763 | $24 |
| Ipratropium | 16 | $403 | $25 |
| Famotidine | 13 | $365 | $28 |
| Montelukast | 19 | $339 | $18 |
2022: 5 drugs
| Dupixent | 11 | $40,097 | $3,645 |
| Xolair | 16 | $38,617 | $2,414 |
| Azelastine | 24 | $2,399 | $100 |
| Fluticasone Propionate | 13 | $348 | $27 |
| Famotidine | 12 | $49 | $4 |
2021: 2 drugs
| Xolair | 13 | $30,533 | $2,349 |
| Azelastine | 23 | $1,632 | $71 |
2018: 1 drug
| Montelukast | 22 | $242 | $11 |
Money from drug and device companies
$264 in 2025
| 2025 | 3 | 10 | None | $264 |
| 2024 | 4 | 4 | None | $130 |
| 2023 | 3 | 4 | $1,300 | $1,440 |
| 2022 | 1 | 1 | None | $97 |
| 2021 | 3 | 16 | None | $253 |
| 2020 | 3 | 5 | None | $208 |
| 2019 | 12 | 25 | $1,613 | $5,481 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Xolair | $232 | 8 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $17 | 1 payment
|
| Arcutis Biotherapeutics | Zoryve | $15 | 1 payment
|
See all 10 published payments
| Novartis Pharmaceuticals | Meals · 2025-11-03 | Rhapsido | $31 |
| Novartis Pharmaceuticals | Meals · 2025-10-16 | Rhapsido | $25 |
| Novartis Pharmaceuticals | Meals · 2025-09-15 | Xolair | $17 |
| Novartis Pharmaceuticals | Meals · 2025-07-29 | None | $25 |
| Novartis Pharmaceuticals | Meals · 2025-07-25 | None | $75 |
| Arcutis Biotherapeutics | Meals · 2025-06-11 | Zoryve | $15 |
| Novartis Pharmaceuticals | Meals · 2025-06-02 | Xolair | $17 |
| Novartis Pharmaceuticals | Meals · 2025-04-29 | Xolair | $18 |
| Novartis Pharmaceuticals | Meals · 2025-02-05 | Xolair | $23 |
| GlaxoSmithKline | Meals · 2025-01-14 | Trelegy Ellipta | $17 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $130
| Genzyme | Dupixent | $66 | 1 payment
|
| Arcutis Biotherapeutics | Zoryve | $27 | 1 payment
|
| Genentech USA | Xolair | $21 | 1 payment
|
| GlaxoSmithKline | Arexvy | $17 | 1 payment
|
2023: $1,440
| GlaxoSmithKline | Nucala | $1,300 | 1 payment
|
| Coloplast | Titan | $119 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $21 | 1 payment
|
2022: $97
| Genzyme | None | $97 | 1 payment
|
2021: $253
| GlaxoSmithKline | Nucala | $130 | 14 payments
|
| Boehringer Ingelheim Pharmaceuticals | None | $102 | 1 payment
|
| Genentech USA | Xolair | $20 | 1 payment
|
2020: $208
| Genzyme | Dupixent | $173 | 3 payments
|
| Genentech USA | Xolair | $21 | 1 payment
|
| GlaxoSmithKline | Nucala | $13 | 1 payment
|
2019: $5,481
| Genentech | Xolair | $5,051 | 6 payments
|
| Genentech USA | Xolair | $153 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $57 | 3 payments
|
| Genzyme | Dupixent | $42 | 2 payments
|
| OptiNose US | Xhance | $40 | 3 payments
|
| GlaxoSmithKline | Nucala | $26 | 2 payments
|
| Novartis Pharmaceuticals | Xolair | $24 | 1 payment
|
| Pfizer | Eucrisa | $24 | 1 payment
|
| Kaleo | Auvi-Q | $18 | 1 payment
|
| ALK-Abello | Odactra | $18 | 1 payment
|
| Shire North American Group | Cinryze | $17 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| AIMMUNE THERAPEUTICS, INC. · A Multicenter, Open-Label, Long-Term Safety Study of Ar101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in A Prior Ar101 Study · 2020 | Their institution | $137,551 |
| AIMMUNE THERAPEUTICS, INC. · A Multicenter, Open-Label, Long-Term Safety Study of Ar101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in A Prior Ar101 Study · 2021 | Their institution | $85,567 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1497190714
- Licence
- CA A133233, NY 293312-1California A133233: Current · expires 2028-09-30
- Trained
- University of California, San Francisco School of Medicine, 2013
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RA0201X (207RA0201X); Federal specialty code 207K00000X (207K00000X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2013-04-30
- NPI last updated
- 2024-04-17
- NPI record certified
- 2024-04-17
This is when the NPI record was last certified, not a medical board exam.